Graft Versus Host Disease – Landscape & Forecast – Disease Landscape & Forecast
Graft versus host disease (GVHD) is a potentially life-threatening complication of allogeneic hematopoietic stem-cell transplantation (HSCT). GVHD is a systemic inflammatory reaction triggered by donor T cells’ recognition of host cell antigens in nontarget tissue as foreign. For decades, steroids have been the first-line therapy for the prevention and treatment of GVHD, but interviewed experts call for better treatments for steroid-refractory patients, as well as better first-line and prophylactic treatments for GVHD. Although development in this space has historically been slow, the pipeline for GVHD therapies is now robust with a number of late-phase agents, including Mesoblast’s Ryoncil (remestemcel-L), Incyte’s itacitinib, Kadmon’s belumosudil, Elsalys / Mediolanum’s Leukotac (inolimomab), and Xenikos’s T-Guard. Here, we examine the clinical and commercial opportunity of these emerging therapies and how they may affect the commercial performance of current therapies, such as AbbVie / Janssen’s Imbruvica and Incyte / Novartis’s Jakafi / Jakavi.
QUESTIONS ANSWERED
- How large is the GVHD population, and how will it change through 2029? What percentage of the GVHD population receives drug treatment?
- How is GVHD currently managed in the United States and EU5? How well does the GVHD pipeline align with unmet needs in the space?
- Which emerging therapies do experts consider most promising? If approved, how would emerging therapies affect the management of GVHD? Which emerging drugs hold the most commercial potential?
- What are some of the key GVHD market drivers and constraints? How will continuing advances in patient and host human leukocyte antigen (HLA) matching affect the market?
CONTENT HIGHLIGHTS
- Geographies: United States and EU5.
- Primary research: Six country-specific interviews with thought-leading GVHD specialists, supported by survey data collected for this study.
- Epidemiology: Diagnosed incident cases of acute and chronic GVHD, diagnosed incident cases of acute GVHD by grade, drug-treated cases of GVHD by country.
- Forecast: Drug-level sales and patient share of key GVHD therapies in 2029.
- Emerging therapies: Late phase / preregistered: 6 drugs; Phase II: >10 drugs; coverage of select preclinical and Phase I products.
Table of contents
- Graft Versus Host Disease - Landscape & Forecast - Disease Landscape & Forecast
- COVID-19
- Key Findings
- Commercial Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Emerging Therapies
- Key Findings
- Key Emerging Therapies
- Key Therapies in Development for Graft Versus Host Disease
- Estimated Launch Dates of Key Emerging Therapies for Graft Versus Host Disease
- JAK Inhibitors
- Stem Cell Therapy
- Photosensitizing Agents
- Serine Protease Inhibitors
- Rho-Associated Protein Kinase 2 Inhibitors
- IL-2R Antagonists
- Immunotoxin-Conjugated Antibodies
- Other Notable Late-Phase Developments
- Early-Phase Pipeline Analysis
- Patient Registries
- Orphan Drug Designation
- Access & Reimbursement Overview
- Methodology
- Bottom-Up Forecasting Overview
- Bottom-Up Forecast Assumptions
- General Sources of Data
- Drug-Treatment Rate Assumptions in Graft Versus Host Disease
- Patient-Share Assumptions in Graft Versus Host Disease
- General Statements About Pricing
- Sources for Drug Prices
- 2019 Exchange Rates
- Price per Treated Day: 2029
- Dosing, Days of Therapy, and Compliance
- Out-Year Forecasting
- Emerging Therapy Prices
- Primary Market Research
- Appendix
- COVID-19
Andrew Russell, Ph.D., is a business insights analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. In this role, he authors reports that distill the findings of his research into pharmaceutical markets related to autoimmune disease and bacterial infection. He worked previously in neurodegenerative disease research at Brigham and Women’s Hospital in Boston. He holds a Ph.D. in cellular and molecular biology from Brandeis University.
